The good news keeps coming for the specialty pharmacy pipeline in 2021. As was mentioned in a blog last month, The Upcoming Specialty Medication Pipeline, about 60% of medications currently under FDA review are accounted for by specialty medications. In addition, many of these are specialty drugs for oncology, hematology, multiple sclerosis, and inflammatory diseases, as well as including new biosimilar medications.
Whether it’s Hurricane Elsa whipping up winds in Florida, the recent heat wave with mercury-busting temperatures out West, or anything in between, it can be a nail-biting experience for patients waiting on essential specialty medications during unusual weather events. But not for BioPlus Specialty Pharmacy patients.
It can sometimes be a bumpy road when it comes to getting essential medications in the hands of patients facing complex or chronic medical conditions, according to a recent survey of more than 400 nurses.
Specialty medications fill a unique and important niche for patients facing complex or chronic conditions. By definition, specialty medications are high-cost medications that call for special monitoring, dose tracking, and/or administration. In other words, they take a special touch.
Scientific progress marches on. There are many specialty medications on the cusp of approval that are worth keeping an eye on in 2021, especially when it comes to specialty drugs for oncology, hematology, multiple sclerosis, and inflammatory diseases.
When it comes to specialty pharmacy medications, 2021 is looking to be an exciting year of new medications cued up for FDA review and (fingers crossed) approval. The pipeline is full, which means that patients will have more choices than ever for treating many complex and challenging conditions.